Tuesday, May 11, 2021 5:32:59 PM
Viatris Inc. Announces Inaugural Quarterly Dividend
Board of Directors declared a quarterly dividend of eleven cents ($0.11) for each issued and outstanding share of the company's common stock. The dividend is payable on June 26, 2021 to stockholders of record at the close of business on May 24, 2021.
Board of Directors declared a quarterly dividend of eleven cents ($0.11) for each issued and outstanding share of the company's common stock. The dividend is payable on June 26, 2021 to stockholders of record at the close of business on May 24, 2021.
Boston MA - Sports Championship City...
Recent VTRS News
- U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain • PR Newswire (US) • 05/18/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:30:24 PM
- Viatris to Present at the Bank of America Securities 2026 Healthcare Conference • PR Newswire (US) • 05/07/2026 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:03:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:47:46 AM
- Viatris Reports First-Quarter 2026 Financial Results • PR Newswire (US) • 05/07/2026 10:59:00 AM
- Viatris Announces Quarterly Dividend • PR Newswire (US) • 05/05/2026 10:59:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:39:32 PM
- Viatris Announces Chief Financial Officer Transition • PR Newswire (US) • 05/04/2026 08:30:00 PM
- Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting • PR Newswire (US) • 05/01/2026 10:59:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:24:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:00:28 PM
- Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 • PR Newswire (US) • 04/13/2026 10:59:00 AM
- Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting • PR Newswire (US) • 04/10/2026 10:59:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 08:31:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 08:30:52 PM
- Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) • PR Newswire (US) • 03/23/2026 10:59:00 AM
- Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 • PR Newswire (US) • 03/19/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:04:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 11:03:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 12:00:16 AM
